Core C will provide statistical and informatics support for all four research projects, Core B (Tissue/Histology), the Developmental Research Program, and the Career Development Program. Specifically, members of the Core will: 1) collaborate with investigators on statistical aspects of the design of in vitro and in vivo laboratory-based studies as new data come to light, and perform t)oth exploratory and confirmatory statistical analyses of data from key experiments;2) perform statistical analyses of single nucleotide polymorphisms (SNPs) and haplotypes in relation to the risk of disease progression and disease-specific survival in SCCHN patients;3) collaborate with basic scientists and clinicians in writing protocols for SPORE-supported clinical trials that are methodologically sound from a statistical perspective, and that will pass scientific, ethical, and regulatory review;4) perform interim analyses of safety for the SPORE-related clinical trials that are underway, and final analyses of the data relating to safety, efficacy, and correlative studies;5) contribute to the review of developmental research proposals, and provide statistical and informatics support for those that are funded;6) maintain and enhance a virtual repository that integrates data from clinical, questionnaire, pathologic, and molecular systems into a single architecture supported by a set of common data elements to facilitate basic-science, clinical, and translational research by the SPORE;7) work with project investigators and UPCI Clinical Research Services to ensure that requisite data are properly recorded for statistical analyses, and that systems for quality assurance and quality control for SPORE-related data are in place;8) continue the development of data-entry, data-mining and data-analysis tools, and a data warehouse for genomic and proteomic data;9) using recorded data elements in the SPORE'S organ-specific database, develop algorithms for study variables that are widely applicable to the SPORE, such as disease progression and recurrence, occurrence of a second primary, treatment with cetuximab, and use of platinum-based treatment regimens;and 10) collaborate with project investigators in writing and preparing progress reports, abstracts, manuscripts, and presentations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097190-09
Application #
8541592
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
9
Fiscal Year
2013
Total Cost
$291,224
Indirect Cost
$86,635
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Pollock, Netanya I; Grandis, Jennifer R (2015) HER2 as a therapeutic target in head and neck squamous cell carcinoma. Clin Cancer Res 21:526-33
Li, Jing; Jie, Hyun-Bae; Lei, Yu et al. (2015) PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res 75:508-18
Johnson, Daniel E (2015) The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. Endocr Relat Cancer 22:T1-17
Sen, Malabika; Paul, Kathleen; Freilino, Maria L et al. (2014) Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects. Mol Med 20:46-56
Parikh, Rahul A; Appleman, Leonard J; Bauman, Julie E et al. (2014) Upregulation of the ATR-CHEK1 pathway in oral squamous cell carcinomas. Genes Chromosomes Cancer 53:25-37
Johnston, Paul A; Sen, Malabika; Hua, Yun et al. (2014) High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines. Assay Drug Dev Technol 12:55-79
Qian, Wei; Wang, Jingnan; Roginskaya, Vera et al. (2014) Novel combination of mitochondrial division inhibitor 1 (mdivi-1) and platinum agents produces synergistic pro-apoptotic effect in drug resistant tumor cells. Oncotarget 5:4180-94
Klein, Jonah D; Sano, Daisuke; Sen, Malabika et al. (2014) STAT3 oligonucleotide inhibits tumor angiogenesis in preclinical models of squamous cell carcinoma. PLoS One 9:e81819
Peyser, Noah D; Grandis, Jennifer R (2014) Genetic mutations in head and neck cancer: utilizing existing treatments. Pharmacogenomics 15:1553-5
Li, Changyou; Egloff, Ann Marie; Sen, Malabika et al. (2014) Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth. Mol Oncol 8:1220-30

Showing the most recent 10 out of 150 publications